* Data presented at peripheral nerve society meeting further support potential benefit of Inotersen​

* ‍Phase 3 neuro-TTR study met both its primary endpoints, Norfolk QOL-DN and MNIS+7, with high statistical significance​

* Treatment with Inotersen resulted in statistically significant benefit in MNIS+7 versus placebo at 8 months of treatment, at 15 months of treatment​

* ‍Continuing to review full data package from neuro-TTR study, prepare regulatory marketing applications for submission this year​

* ‍Results continue to support favorable benefit-risk profile for Inotersen in patients with FAP​ Source text for Eikon: Further company coverage: